HRA Pharma in deal with Chemo Iberica for ulipristal emergency contraceptive in Latin America

Privately-held French firm HRA Pharma and Spain’s Chemo Iberica have entered into an exclusive agreement to supply and distribute ulipristal acetate 30mg (UPA) in Central and South America. UPA is a novel emergency contraceptive developed by HRA Pharma, indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. It already available in a number of markets under trade names such as ellaOne, ella and Esmya.

Under the terms of the agreement, financial terms of which are not disclosed, HRA Pharma will file for marketing approvals for UPA in Argentina, Belize, Brazil, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Uruguay and Venezuela. Following marketing approval, Chemo will distribute the product in these countries.

Existing marketing arrangements